Clinical Trial Detail

NCT ID NCT03591510
Title A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Cytarabine

Cytarabine + Etoposide

Cytarabine + Mitoxantrone

Cytarabine + Fludarabine + Idarubicin

Cytarabine + Daunorubicin + Fludarabine

Cytarabine + Daunoxome + Fludarabine

Midostaurin

Age Groups: child

Additional content available in CKB BOOST